Results 201 to 210 of about 1,505,630 (287)

Model‐Based Analysis with Mechanistic Insights to CAR‐T‐Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin, Martin Bergstrand, Ana Ruiz‐Garcia, Simone Filosto, Rhine Shen   +4 more
wiley   +1 more source

T-cell protrusions enable fast, localised initiation of chimeric antigen receptor signalling. [PDF]

EMBO J
Rodilla-Ramirez C, Carai G, Fox E, Zehtabian A, Adam H, Dallio K, Lazki-Hagenbach P, Ewers H, Su X, Bottanelli F.   +9 more
europepmc   +1 more source

Chimeric antigen receptor T-cells in multiple myeloma: Present and future

This is a brief summary of various general contemporary topics regarding chimeric antigen receptor (CAR) T-cells in multiple myeloma (MM)
Plata, Carlos
core  

The Multiple Criteria Qualitative Value‐Based Pricing Framework “MARIE” for Novel Cell and Gene Therapy

Clinical Pharmacology &Therapeutics, EarlyView.
When setting the price of cell and gene therapies in Japan, the factors considered include the manufacturing and operating costs of the new drug or a comparator, leading to discrepancies between price and values, in particular those specific to cell and gene therapies.
Akina Takami, Ataru Igarashi
wiley   +1 more source

A Feeder Cell-Free System for Chimeric Antigen Receptor Gene Transduction Into Natural Killer Cells. [PDF]

Bio Protoc
Kubo N, Baba M, Suzuki Y, Kasahara Y, Hosokai R, Imamura M, Saitoh A, Imai C.   +7 more
europepmc   +1 more source

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma. [PDF]

Blood Cancer J
Sharp J, Bhatta S, Huang JJ, Thomas CJ, Elghawy O, Fitzgerald L, Reef D, Teferra A, Voorhees TJ, Gupta S, Grover NS, Barta SK, Shadman M, Epperla N.   +13 more
europepmc   +1 more source

Goofy/123Cre lineage tracing differentiates olfactory and vomeronasal neurons from GnRH‐1 and terminal nerve neurons during neuronal migration and reveals additional olfactory placode‐derived cells in the brain

Developmental Dynamics, EarlyView.
Abstract The olfactory placode (OP) generates a broad array of chemosensory neurons in the nasal region, including olfactory sensory neurons, vomeronasal sensory neurons, neurons of the septal organ, and Grueneberg ganglion. During invagination, the OP also generates migratory neuronal populations, including gonadotropin‐releasing hormone‐1 (GnRH‐1 ...
Enrico Amato Jr., Mia V. Call, Noah M. LeFever, Mya Aviles‐Carlos, Nikki M. Dolphin, Paolo E. Forni   +5 more
wiley   +1 more source

Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination. [PDF]

Nat Commun
Warmuth L, Dötsch S, Trebo M, Bellucci S, Engels S, Valdivia Manrique R, Moukarzel K, Schütz JM, Hammel M, Straub A, Wagner S, Hochholzer A, Salinno C, Seigner J, Zajc CU, Schmidt GP, Michael J, Nerreter T, Hudecek M, Traxlmayr MW, Casucci M, Riddell SR, Poltorak MP, Busch DH, D'Ippolito E.   +24 more
europepmc   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source